Call Us Now

+91 9606900005 / 04

For Enquiry

legacyiasacademy@gmail.com

Alzheimer’s Disease

Context:

Recently, The Food and Drug Administration approved a new Alzheimer’s drug that may modestly slow the pace of cognitive decline early in the disease but also carries risks of swelling and bleeding in the brain.

Relevance:

GS III- Science and technology

Dimensions of the Article:

  1. About the drug lecanemab
  2. Alzheimer’s Disease

About the drug lecanemab

  • The approval of the drug, lecanemab, to be marketed as Leqembi, is likely to generate considerable interest from patients and physicians.
  • The approval of the drug, lecanemab, to be marketed as Leqembi, is likely to generate considerable interest from patients and physicians.
  • Studies of the drug — an intravenous infusion administered every two weeks — suggest it is more promising than the scant number of other treatments available.
  • Still, several Alzheimer’s experts said it was unclear from the medical evidence whether Leqembi could slow cognitive decline enough to be noticeable to patients.

Alzheimer’s Disease

  • Alzheimer’s disease is a chronic neurodegenerative disease that usually starts slowly and gradually worsens over time.
  • It is the cause of 60–70% of cases of dementia.
  • The most common early symptom is difficulty in remembering recent events.
  • The cause of Alzheimer’s disease is poorly understood, about 70% of the risk is believed to be inherited from a person’s parents, with many genes usually involved.
  • Other risk factors include a history of head injuries, depression, and hypertension.
  • No treatments stop or reverse its progression, though some may temporarily improve symptoms.

-Source: Indian Express


February 2023
MTWTFSS
 12345
6789101112
13141516171819
20212223242526
2728 
Categories